Quantcast
Last updated on April 18, 2014 at 15:05 EDT

Latest Phosphoinositide 3-kinase inhibitor Stories

2014-04-03 08:29:00

- More than 50 abstracts highlight breadth and depth of Novartis Oncology pipeline and ability to test various combinations early to target multiple pathways EAST HANOVER, N.J., April 3, 2014 /PRNewswire/ -- Novartis announced today that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research (AACR), April 5-9, 2014 in San Diego, CA. The AACR annual meeting highlights basic, translational...

2013-02-15 12:21:29

MUMBAI, February 15, 2013 /PRNewswire/ -- Bharatbook.com is pleased to announce a new research report on Drivers of M&A in 2013-2016: PI3Ks and BTK Inhibitors ( http://www.bharatbook.com/healthcare-market-research-reports/drivers-of-m-a-in-2013-2016-pi3ks-and-btk-inhibitors.html ) New targets/drugs remain an evergreen medical need to address the unmet need of drug resistance in the treatment of cancer. Large global pharma are constantly on the hunt for drugs with...

2012-11-08 12:27:27

BOULDER, Colo., Nov. 8, 2012 /PRNewswire/ -- At its R&D Investor event earlier today, Novartis provided an update on the clinical development strategy for MEK162 (ARRY-162). Novartis intends to initiate pivotal trials in patients with NRAS mutant melanoma during 2013, with the goal of regulatory submissions on or after 2016. In addition, Novartis announced plans to pursue clinical development in combination with a Raf inhibitor, in BRAF mutant melanoma, with regulatory submissions...